ELVNEnliven Therapeutics, Inc.

HealthcareUSD
$60.87

The financials

Enliven Therapeutics, Inc. by the numbers

Enliven Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$37M−$29Mn/a
Net income−$32M−$25Mn/a
Diluted EPS−$0.49−$0.49n/a

Biotechnology

Ranks #12 of 145 by Smart Score

Compare peers
IDYA+0.03%
IDEAYA Biosciences, Inc.
BEAM+0.09%
Beam Therapeutics Inc.
GPCR+0.19%
Structure Therapeutics Inc.
DYN+1.4%
Dyne Therapeutics, Inc.
QURE+0.51%
uniQure N.V.
TLX-0.37%
Telix Pharmaceuticals Limited